Harvard Bioscience Inc.
HBIO | NASDAQ
$8.90
+$0.10 (+1.14%)
At close: Oct 30, 2026, 4:00 PM ET
$8.90
$0.00 (0.00%)
After-hours:
Oct 30, 2026, 7:30 PM ET
Fiscal Year Period Ending | FY 2025 Dec 31, 2025 | FY 2024 Dec 31, 2024 | FY 2023 Dec 31, 2023 | FY 2022 Dec 31, 2022 | FY 2021 Dec 31, 2021 | FY 2020 Dec 31, 2020 |
|---|---|---|---|---|---|---|
PE Ratio | -0.52 | -7.54 | -66.46 | -12.04 | -992.96 | -21.45 |
PEG Ratio | 0 | -0.03 | 1.02 | 0 | 10.30 | -0.32 |
PS Ratio | 0.34 | 0.98 | 2.02 | 1.01 | 2.39 | 1.62 |
PB Ratio | 2.16 | 1.45 | 3.11 | 1.59 | 3.41 | 2.16 |
P/FCF Ratio | 5.29 | -50.39 | 19.37 | -261.90 | 4.25K | 20.27 |
P/OCF Ratio | 4.41 | 63.80 | 16.18 | 99.58 | 225.37 | 17.77 |
OCF/S Ratio | 7.77 | 1.53 | 12.50 | 1.02 | 1.06 | 9.14 |
Debt / Equity Ratio | 3.22 | 0.70 | 0.59 | 0.75 | 0.68 | 0.75 |
Quick Ratio | 1.25 | 0.40 | 0.92 | 1.06 | 1.34 | 1.40 |
Current Ratio | 2.20 | 0.82 | 1.85 | 2.20 | 2.43 | 2.46 |
Asset Turnover | 1.08 | 0.74 | 0.82 | 0.78 | 0.73 | 0.65 |
Interest Coverage | -0.13 | -1.94 | 0.53 | -2.72 | 1.34 | 0.05 |
Return on Equity | -412.84% | -19.58% | -4.67% | -13.18% | -0.35% | -10.19% |
Return on Assets | -70.81% | -9.80% | -2.49% | -6.55% | -0.18% | -5% |
Return on Invested Capital | -1.04% | -5.66% | 1.60% | -5.41% | 1.45% | 0.16% |
Dividend Yield | n/a | n/a | n/a | n/a | n/a | n/a |
Payout Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
FCF Payout Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit Margin | 53.01% | 58.18% | 58.86% | 53.66% | 56.90% | 56.85% |
Net Profit Margin | -65.51% | -13.18% | -3.04% | -8.40% | -0.24% | -7.65% |
Pretax Profit Margin | -66.30% | -12.39% | -2.28% | -8.10% | -0.12% | -7.14% |
Operating Profit Margin | -0.73% | -6.60% | 1.69% | -6.12% | 1.74% | 0.22% |
FCF Margin | 6.49% | -1.94% | 10.44% | -0.39% | 0.06% | 8.01% |
EBITDA Margin | -53.75% | -1.57% | 7.16% | 0.83% | 7.59% | 5.06% |
Add to Watchlist
Select watchlists to add or remove HBIO